DNDI asaq
Registration Updates
December 2007:
Recent clinical studies support the use of ASAQ, and over 1 million treatments distributed in 2007.
July 2007:
registration status and how to get access at a ‘no profit-no loss price’
April 2007:
read registration update
read DNDi/sanofi-aventis position paper on Financial Times article
ASAQ in a few words
- A drug combination that meets the latest WHO guidelines for malaria treatment in Africa

- An innovative fixed-dose formulation
A simple dosing regimen:
  • 1 tablet per day for 3 days for infants, children and adolescents
  • 2 tablets once a day for 3 days for adults
  • Presentations specifically adapted to children
  • State-of-the-art galenical formulation
  • Optimized dose ratio to avoid over- and under-dosage

  • In the child’s lower hand, the single ASAQ tablet per day is shown in comparison with the upper hand containing 4 tablets needed per day with current treatments.
    - A combination of well-known drugs with well-documented track records
    of efficacy and safety

    - A commitment to make it available to all patients, right from the start
  • <US$1 for adults and <US$0.50 for children in public markets
  • Not patented
  • - Highest standards of quality enforced through the entire manufacturing process

    - The concrete result of an innovative partnership between DNDi and
    sanofi-aventis

     
    Version française English version
    contents
     
    Press release
    Video Press release
    Press Conference Video
    Web video
    ASAQ in a few words
    ASAQ product profile
    ASAQ... Adapted
    ASAQ...Simple
    ASAQ... Accessible
    ASAQ... Quality
    Clinical Data
    An innovative partnership
    ASAQ: Contribution of DNDi
    and FACT Partners
    ASAQ: Contribution of sanofi-aventis
    DNDi: addressing the therapeutic needs of the most neglected
    sanofi-aventis
    Background on malaria
    ASAQ in the media
    Governments welcome ASAQ!ItalyGermanyEuropean UnionUnited KingdomNetherlands
    MSF welcomes ASAQ
    Product launch
    dates to be aware of

    Paris - 1 March
    11 am - 1pm: Press briefing
    Centre d'Accueil de la Presse Étrangère - Maison de Radio France
    Paris - 1 March
    6 pm - 7:30 pm: Expert Roundtable "Transforming Hope into Equitable Access for Malaria Patients in Africa" la Maison Internationale Cite Universitaire
    Washington DC - 9 March
    8 am -9:30 am

    Read the PLoS guest blog of Jean-René Kiechel & Bernard Pecoul:
    "Innovative Partnership Brings New ACT Free of Patent"
    Original FACT Partners
    (who signed onto the original EU INCO-DEV grant in 2002):
    Instituto de Tecnologia em Farmacos of Farmanguinhos Centre National de Recherche et de Formation sur le Paludisme (CNRFP) Mahidol University Médecins Sans Frontières UNICEF-UNDP-World Bank-WHO's Special Programme for Research and Training in Tropical Diseases (TDR) Université Victor Segalen Bordeaux II (TROPIVAL) University of Oxford University Sains Malaysia Since the main FACT partners formed in 2002, many additional partners are contributing to this project.read more
    Links of related interest: London School of Hygiene & Tropical Medicine Malaria Consortium Medicines for Malaria Venture (MMV) MSF Access President's Malaria Initiative Roll Back Malaria UNITAID WHO Global Malaria Programme (GMP)